Valuation: Cingulate Inc.

Market Cap 67.76M 60.39M 55.91M 50.59M 95.32M 6.39B 96.45M 670M 263M 3.36B 254M 249M 10.71B P/E 2026 *
-2.19x
P/E 2027 * -4.48x
Enterprise Value 67.76M 60.39M 55.91M 50.59M 95.32M 6.39B 96.45M 670M 263M 3.36B 254M 249M 10.71B EV / Sales 2026 *
-
EV / Sales 2027 * 3.04x
Free-Float
71.71%
Yield 2026 *
-
Yield 2027 * -
1 day+2.87%
1 week+1.97%
Current month-5.86%
1 month-10.90%
3 months-2.41%
6 months-20.48%
Current year+7.37%
1 week 4.12
Extreme 4.12
4.7
1 month 4.12
Extreme 4.12
5.22
Current year 3.16
Extreme 3.16
11.89
1 year 3.16
Extreme 3.16
11.89
3 years 1.8
Extreme 1.8001
152.4
5 years 1.8
Extreme 1.8001
1,236
10 years 1.8
Extreme 1.8001
1,236
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 63 01/01/2018
Chief Tech/Sci/R&D Officer 69 01/01/2018
Chief Executive Officer 51 01/05/2012
Director TitleAgeSince
Director/Board Member 87 01/06/2018
Director/Board Member 59 01/06/2018
Chairman 51 01/05/2012
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 A Free

Founder

4,293 0.0295%
7/16/26 A Free

Director

20,000 0.1485%
7/16/26 A Free

Founder

80,000 0.5940%
Change 5-day change 1-year change 3-year change Capi.($)
+2.87%+1.97%+21.04%-95.87% 65.87M
-0.21%-4.43%+44.40%+74.13% 66.34B
+0.82%+5.41%+8.05%+73.53% 54.82B
-0.22%+6.53%+11.68%+87.32% 52.92B
+3.28%+5.58%+26.51%+50.05% 44.09B
+0.51%+9.95%+22.40%+133.92% 43.72B
-1.15%+0.39%+263.21%+594.60% 42.13B
+0.10%+9.90%+16.11%+59.33% 33.96B
-3.85%-2.38%+32.55%+2.88% 26.17B
+0.69%+5.60%+36.60%+26.94% 23.37B
Average +0.28%+4.46%+48.25%+100.68% 38.76B
Weighted average by Cap. +0.14%+4.54%+50.30%+127.44%

Financials

2026 *2027 *
Net sales - 22.27M 19.84M 18.37M 16.63M 31.32M 2.1B 31.69M 220M 86.43M 1.1B 83.53M 81.79M 3.52B
Net income -27.95M -24.91M -23.06M -20.87M -39.31M -2.64B -39.78M -276M -108M -1.39B -105M -103M -4.42B -15.06M -13.42M -12.42M -11.24M -21.18M -1.42B -21.43M -149M -58.44M -747M -56.48M -55.3M -2.38B
Net Debt - -
Projected Income Statement - Annual - Cingulate Inc.
Logo Cingulate Inc.
Cingulate Inc. is a biopharmaceutical company. The Company offers Precision Timed Release (PTR), which is a drug delivery platform technology to build and advance a pipeline of pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety. Its PTR platform incorporates an erosion barrier layer (EBL) designed to allow for the release of drug substances at specific, pre-defined time intervals. It develops stimulant medications which include CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of ADHD across all three patient segments: children (aged 6 -12), adolescents (aged 13-17), and adults (aged 18+). It also develops CTx-2103 (buspirone), for the treatment of anxiety.
Employees
14
Date Price Change Volume
21/10/26 $4.660 +2.87% 132,401
20/10/26 $4.530 +3.90% 108,412
19/10/26 $4.360 0.00% 47,818
16/10/26 $4.360 -0.68% 228,612
15/10/26 $4.390 -3.94% 175,957
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cingulate Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.660USD
Average target price
21.20USD
Spread / Average Target
+354.94%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cingulate Inc.
  1. Stock Market
  2. Stocks
  3. CING Stock